Prognostic value of somatostatin receptor subtype 2 expression in colorectal cancer.
The clinical relevance of the somatostatin receptor subtype 2 (sst2) is well defined in neuroendocrine tumors but it is still a matter of debate whether its expression may have a role also in other tumors not arising from the neuroectoderm. We investigated the prognostic value of the expression levels of sst2 mRNA in a consistent group of patients affected by colorectal cancer. Survival analysis of cancer-related death showed that patients with a high sst2 mRNA expression had an unfavourable outcome (p=0.037) and a significantly shorter disease-free survival (p=0.008). Surprisingly, our findings suggest that sst2 gene overexpression is a feature of colorectal tumors that have a negative outlook; in addition, it may allow additional insight into conventional therapeutic approaches for more aggressive tumors, whose prognosis needs to be improved.
Raggi
Claudia Casini
CC
Clinical Biochemistry, Department of Clinical Physiopathology, University of Florence, viale Pieraccini 6, Florence, Italy.
Cianchi
Fabio
F
Valanzano
Rosa
R
Smith
Michela Cameron
MC
Serio
Mario
M
Maggi
Mario
M
Orlando
Claudio
C
D015179:Colorectal Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000401:mortality; D015870:Gene Expression; D006801:Humans; D011379:Prognosis; D016016:Proportional Hazards Models; D012333:RNA, Messenger / Q000096:biosynthesis; D012334:RNA, Neoplasm / Q000096:biosynthesis; D017481:Receptors, Somatostatin / Q000096:biosynthesis* / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis
D012333:RNA, Messenger; D012334:RNA, Neoplasm; D017481:Receptors, Somatostatin; C093733:somatostatin receptor 2